Please enable Javascript
Conferences
Partners
Expert Interviews
Subscribe
Heme Today
Anemia
Deep Vein Thrombosis
Essential Thrombocythemia
Hemophilia
Immune Thrombocytopenic Purpura
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Neoplasms
PNH
Polycythemia Vera
Pulmonary Embolism
Sickle Cell Disease
Thrombocytopenia
Thrombophilia
Thrombosis
Thrombotic Thrombocytopenic Purpura
Venous Thromboembolism
von Willebrand Disease
Nephrology Times
Acute Kidney Injury
ADPKD
Anemia and Kidney Disease
Chronic Kidney Disease
COVID-19 and Kidney Disease
Diabetes and Hypertension
End-Stage Renal Disease
Gout
Hyperkalemia
IgAN
Kidney Transplantation
Metabolic Acidosis
Breast Cancers Today
HER2 Breast Cancer
HR Breast Cancer
Triple-Negative Breast Cancer
Genetics & Breast Cancer
Cardiology
Atherosclerotic Disease
Atrial Fibrillation
Heart Failure
Hypertension
Interventional Cardiology
Lipid Management
Practice Tips With Dr. Lichaa
Preventive Cardiology
Stroke
Oncology
Breast Cancer
Gynecologic Cancer
Head and Neck Cancer
Skin Cancer
Sleep
Urology
More
Diabetes
Ophthalmology
— Demodex Blepharitis
Neurology
Rheumatology
Gastroenterology
Pulmonology
Infectious Diseases
— HIV
Health and Wellness
Lupus
Future of Medicine
Orthopedics
Pharmacology
Career News
Zachary Bessette
Zachary Bessette, Managing Editor
Articles by Zachary Bessette
CheckMate 9DW Expanded Analyses: Ipi/Nivo Versus Len/Sor for Unresectable HCC
Zachary Bessette
Liver Cancer
|
January 23, 2025
Additional analyses from the CheckMate 9DW study shed further light on the clinical efficacy and safety of ipi/nivo for uHCC.
Read More
NIR-B Trial: Niraparib in BRCA-Mutated Unresectable or Recurrent BTC, Pancreatic, Other GI Cancers
Zachary Bessette
Bile Duct Cancer
|
January 23, 2025
Results of NIR-B trial sheds light on the clinical utility of niraparib in patients with BRCA-mutated GI cancers.
Read More
Predicting Preoperative GEP-NET Grade With an Automated Radiomics Model
Zachary Bessette
GEP-NETs
|
January 23, 2025
A novel auto-segmentation model and radiomics signature may help with preoperative clinical decision-making for GEP-NETs.
Read More
FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection
Zachary Bessette
Colorectal Cancer
|
January 8, 2025
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
Read More
Does Adding Preoperative CRT to Perioperative Chemotherapy Improve Survival for Resectable Gastric Cancer?
Zachary Bessette
Gastric Cancer
|
September 17, 2024
The addition of preop CRT to periop chemo may not have added OS benefit for patients with resectable G/GEJ adenocarcinoma.
Read More
CABINET: Updated PFS, Subgroup Analyses of Cabozantinib Versus Placebo for Advanced NET
Zachary Bessette
GEP-NETs
|
September 13, 2024
Cabozantinib continues to demonstrate significant improvement in PFS in extra-pancreatic or pancreatic neuroendocrine tumors.
Read More
OrigAMI-1: Amivantamab Plus FOLFOX or FOLFIRI for Metastatic CRC
Zachary Bessette
Colorectal Cancer
|
September 13, 2024
Amivantamab plus chemo shows encouraging and durable antitumor activity for anti-EGFR-naïve RAS/RAF wild-type mCRC.
Read More
FDA Approves Atezolizumab, Hyaluronidase-tqjs Subcutaneous Injection for HCC
Zachary Bessette
Liver Cancer
|
September 19, 2024
FDA approval comes after the IMscin001 trial, an open-label, multi-center, international analysis of adult patients.
Read More
Sotorasib, Panitumumab, FOLFIRI for First-Line KRAS G12C-Mutated mCRC
Zachary Bessette
Colorectal Cancer
|
September 12, 2024
The CodeBreaK 101 study assessed the safety and efficacy of soto, pani, and FOLFIRI for KRAS G12C-mutated mCRC.
Read More
HIMALAYA: 5-Year OS Update of Tremelimumab Plus Durvalumab for Unresectable HCC
Zachary Bessette
GI Cancer
|
December 7, 2024
STRIDE shows “unprecedented” 5-year survival benefit, with no additional serious safety events, for patients with uHCC.
Read More
KEYNOTE-811: Final OS for Pembrolizumab Plus Trastuzumab, Chemo for HER2-Positive G/GEJ Adenocarcinoma
Zachary Bessette
Gastric Cancer
|
December 7, 2024
These data may support the approval of pembro plus trastuzumab and chemo in patients with HER2+ metastatic G/GEJ cancer.
Read More
RECAST: Updated Analysis of FOLFIRI, Ramucirumab Versus FOLFOXIRI, Ramucirumab for Metastatic CRC
Zachary Bessette
Colorectal Cancer
|
September 11, 2024
The latest data from the RECAST trial shed light on FOLFIRI plus RAM for patients with metastatic CRC.
Read More
TACE Plus Irinotecan, Mitomycin C Versus TACE Plus Doxorubicin for Intermediate-Stage HCC
Zachary Bessette
GI Cancer
|
December 7, 2024
A phase 2 trial comparing DEB-TACE with irinotecan, mitomycin C vs DEB-TACE with doxorubicin for intermediate-stage HCC.
Read More
HAIC Plus Sintilimab, Bevacizumab Biosimilar for Patients With uHCC, Child-Pugh B Liver Function
Zachary Bessette
GI Cancer
|
December 7, 2024
FOLFOX-HAIC plus sintilimab and IBI305 demonstrates promising safety and efficacy in uHCC, Child-Pugh B liver function.
Read More
FDA Accepts sBLA for Nivo/Ipi as First-Line Treatment of Unresectable HCC
Zachary Bessette
Unresectable HCC
|
August 21, 2024
The FDA's decision to accept the sBLA is based on the encouraging results of the phase 3 CheckMate-9DW study.
Read More
Integrated 18F-FDG PET/MRI Versus PET/CT in Malignant Tumor Liver Metastasis, Lymphoma Hepatic Infiltration
Zachary Bessette
Liver Cancer
|
June 11, 2024
Integrated PET/MRI may be superior to PET/CT in diagnosing malignant tumor liver metastasis/lymphoma hepatic infiltration.
Read More
NEOPRISM-CRC: Neoadjuvant Pembrolizumab for Early-Stage Deficient-MMR/MSI-High CRC
Zachary Bessette
Colorectal Cancer
|
June 2, 2024
Neoadjuvant pembrolizumab may be effective and safe for early-stage dMMR/MSI-high colorectal cancer.
Read More
ORCHESTRA Primary Outcome Analysis: Additional Tumor Debulking for Multiorgan mCRC
Zachary Bessette
Colorectal Cancer
|
June 2, 2024
The ORCHESTRA trial does not support additional tumor debulking to improve OS for patients with multiorgan mCRC.
Read More
Surgery Versus Thermal Ablation for Small-Size Colorectal Liver Metastases
Zachary Bessette
Colorectal Cancer
|
June 2, 2024
Thermal ablation may offer shorter hospital stay and improved local control for small-size colorectal liver metastases.
Read More
UNION: Longitudinal ctDNA for Predicting Response to Short-Course Rectal Cancer Neoadjuvant RT
Zachary Bessette
ASCO 2024: Focus on GI Oncology
|
June 2, 2024
A phase 3 study offers valuable insights into the dynamic landscape of neoadjuvant therapy for LARC management.
Read More
Load More